NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
31/12/2024
Voltar para busca
Dado oficial do USPTO
LASANTH
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
LASANTH
ST13
US500000090236132Classe
35, 42, 45
Pedido
90236132
Registro
7634013
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
47
Atualização mais recente
31/12/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
35, 42, 45
Data de depósito
05/10/2020
Data de registro
31/12/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/12/2024
Última transação
31/12/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2023-10-00
Primeiro uso no comércio
2023-10-00
Código do desenho
4
Tipo de titular
16
Localização do titular
Whitehouse Station, NJ
Examinador
ALBANO, ASHLEY
Unidade examinadora
L50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Canopy Biopharma LLC
Representantes
Brian J. Focarino COOLEY LLP
Classificação técnica
Classes Nice
Classe 35Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Business consulting services in the field of regulatory compliance; business development services; business strategy development services; business consulting and management in the field of clinical trialsregulatory submission management on behalf of medicalpharmaceuticalbiopharmaceutical and biotechnology companies to assist them with clinical researchclinical trials and applications for drug approval; regulatory submission managementassisting others in preparing applications for medical technologiesmedicationspharmaceuticalbiopharmaceuticalsbiotechnology with governmental regulatory bodies around the world; regulatory submission managementproviding simultaneous multiple country submissions of applications for the registration and approval of medical technologiesmedicationspharmaceuticalbiopharmaceuticalsbiotechnology; providing information online regarding regulatory submission management; business management consultingstrategic planning and business advisory services provided to medicalmedical technologypharmaceuticalbiopharmaceuticalbiotechnology companiesgovernment agencieseducational and research institutionsin the fields of biologics and pharmaceuticals; providing consulting services in the field of regulatory submission management to medical companies to assist them with applications for drug approval; regulatory submission managementassisting others in preparing applications for new drugs with governmental regulatory bodies; business consulting services in the field of biologics and pharmaceuticals
Classe 42
Product research and development for others in the fields of biologics and pharmaceuticals; quality management servicesquality evaluation and analysisquality assurance and quality control in the field of biologics and pharmaceuticals; scientific consulting and research services relating to the field of pharmaceuticals and life sciencesbiologymedicine; consulting services in the fields of biotechnology and pharmaceuticalsdesigndevelopmenttechnical verification and technical validation of manufacturing and filling processesdrug formulationstesting protocols and analytical methods; scientific and technological servicesscientific researchanalysistestingrelated scientific studies in the field of chemistry and molecular biologybiologics and protein detectioncharacterizationanalysis and testing
Classe 45
Regulatory compliance consulting servicesreviewing standards and practices to assist clients with compliance with governmental lawsregulations and rules in the fields of medical technologiesmedicationsbiopharmaceuticalsbiotechnology; providing technical regulatory affair consulting services directed to medicalmedical technologybiopharmaceuticalbiotechnology companies in order to assure compliance with food and drug administration's laws and regulations; provision of information online pertaining to regulatory compliance in the fields of medical technologiesmedicationsbiopharmaceuticalsbiotechnology; and regulatory compliance consulting in the fields of biologics and pharmaceuticals
Publicações
Histórico de despachos e eventos da marca no USPTO.
47 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
31/12/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
06/12/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
06/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/11/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/11/2024
ALIE
ASSIGNED TO LIE
05/11/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/08/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
17/07/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/07/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/07/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/07/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
29/05/2024
GNRT
NON-FINAL ACTION E-MAILED
29/05/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
29/05/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
30/04/2024
IUAF
USE AMENDMENT FILED
26/04/2024
EISU
TEAS STATEMENT OF USE RECEIVED
26/04/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/10/2023
EX5G
SOU EXTENSION 5 GRANTED
04/10/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/10/2023
EXT5
SOU EXTENSION 5 FILED
26/09/2023
EEXT
SOU TEAS EXTENSION RECEIVED
26/09/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
25/04/2023
EX4G
SOU EXTENSION 4 GRANTED
23/04/2023
EXT4
SOU EXTENSION 4 FILED
23/04/2023
EEXT
SOU TEAS EXTENSION RECEIVED
23/04/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
21/10/2022
EX3G
SOU EXTENSION 3 GRANTED
19/10/2022
EXT3
SOU EXTENSION 3 FILED
19/10/2022
EEXT
SOU TEAS EXTENSION RECEIVED
19/10/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
21/05/2022
EX2G
SOU EXTENSION 2 GRANTED
19/05/2022
EXT2
SOU EXTENSION 2 FILED
19/05/2022
EEXT
SOU TEAS EXTENSION RECEIVED
19/05/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
29/09/2021
EX1G
SOU EXTENSION 1 GRANTED
27/09/2021
EXT1
SOU EXTENSION 1 FILED
27/09/2021
EEXT
SOU TEAS EXTENSION RECEIVED
27/09/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/06/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/04/2021
PUBO
PUBLISHED FOR OPPOSITION
06/04/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/03/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/03/2021
DOCK
ASSIGNED TO EXAMINER
02/03/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/11/2020
NWAP
NEW APPLICATION ENTERED
08/10/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LASANTH ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.